FDA orphan drug designations for lysosomal storage disorders – a cross sectional analysis
Sven F. Garbade, Matthias Zielonka, Konstantin Mechler, Stefan Kölker, Georg F. Hoffmann, Christian Staufner, Eugen Mengel, View ORCID ProfileMarkus Ries
doi: https://doi.org/10.1101/2020.01.05.20016568
Sven F. Garbade
1Division of Pediatric Neurology and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany
PhDMatthias Zielonka
1Division of Pediatric Neurology and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany
MDKonstantin Mechler
3Department of Child and Adolescent Psychiatry and Psychotherapy & Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
MDStefan Kölker
1Division of Pediatric Neurology and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany
MDGeorg F. Hoffmann
1Division of Pediatric Neurology and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany
MDChristian Staufner
1Division of Pediatric Neurology and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany
MDEugen Mengel
4SphinCS GmbH, Science for LSD, Hochheim, Germany
MDMarkus Ries
1Division of Pediatric Neurology and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany
2Center for Rare Diseases, University Hospital Heidelberg, Heidelberg, Germany
5Center for Virtual Patients, Medical Faculty, University of Heidelberg, Heidelberg, Germany
MD PhDData Availability
all data generated or analysed during this study are included in this published article
Posted January 14, 2020.
FDA orphan drug designations for lysosomal storage disorders – a cross sectional analysis
Sven F. Garbade, Matthias Zielonka, Konstantin Mechler, Stefan Kölker, Georg F. Hoffmann, Christian Staufner, Eugen Mengel, Markus Ries
medRxiv 2020.01.05.20016568; doi: https://doi.org/10.1101/2020.01.05.20016568
FDA orphan drug designations for lysosomal storage disorders – a cross sectional analysis
Sven F. Garbade, Matthias Zielonka, Konstantin Mechler, Stefan Kölker, Georg F. Hoffmann, Christian Staufner, Eugen Mengel, Markus Ries
medRxiv 2020.01.05.20016568; doi: https://doi.org/10.1101/2020.01.05.20016568
Subject Area
Subject Areas
- Addiction Medicine (376)
- Allergy and Immunology (690)
- Anesthesia (185)
- Cardiovascular Medicine (2780)
- Dermatology (237)
- Emergency Medicine (418)
- Epidemiology (12430)
- Forensic Medicine (10)
- Gastroenterology (787)
- Genetic and Genomic Medicine (4297)
- Geriatric Medicine (397)
- Health Economics (705)
- Health Informatics (2776)
- Health Policy (1029)
- Hematology (371)
- HIV/AIDS (882)
- Medical Education (406)
- Medical Ethics (113)
- Nephrology (455)
- Neurology (4072)
- Nursing (218)
- Nutrition (603)
- Oncology (2154)
- Ophthalmology (608)
- Orthopedics (252)
- Otolaryngology (313)
- Pain Medicine (257)
- Palliative Medicine (79)
- Pathology (480)
- Pediatrics (1152)
- Primary Care Research (473)
- Public and Global Health (6677)
- Radiology and Imaging (1457)
- Respiratory Medicine (889)
- Rheumatology (425)
- Sports Medicine (354)
- Surgery (467)
- Toxicology (57)
- Transplantation (194)
- Urology (172)